This hot biotech stock could have a lot more room to run.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the best biotech stocks to buy according to Wall Street analysts. On ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of ...

Applied’s lead candidate is a selective aldose reductase inhibitor called govorestat, an asset that failed to hit primary endpoints in late-stage trials for a progressive neuromuscular disease called ...

MPM BioImpact fully exited its position in Crinetics Pharmaceuticals during the third quarter, a move disclosed in the fund’s November 14 SEC filing. The transaction reduced assets by approximately ...

Learn more about whether Immunocore Holdings plc or Ultragenyx Pharmaceutical Inc. is a better investment based on AAII's A+ ...

With regulators across Asia-Pacific easing pathways for new therapies, Dimerix is positioning DMX-200 for one of the world’s ...

In the northwest corner of Sioux Falls, an 80-acre campus opened its first building this year dedicated entirely to expanding ...

Seventy-three pharmaceutical, biotechnology and medical device companies from mainland China filed for IPOs in Hong Kong this year, a review by BioWorld found. In the second half of 2025, 43 new ...

Ultragenyx Pharmaceutical stock reacts to shifting sentiment Ultragenyx Pharmaceutical (RARE) has been quietly recalibrating investor expectations, with the stock up about 10% over the past month even ...